Botox boosts Allergan profit
Net income increased to $246.6 million (€172m), or 79 cents a share, from $240.1 million (€169.2m), or 78 cents, a year earlier, the Irvine, California-based company said. Earnings, excluding some items, were 96 cents a share, topping the average estimate of 95 cents from 21 analysts surveyed by Bloomberg. Sales rose to $1.42 billion from $1.25bn a year ago.
Revenue from Allergan’s top-selling product, Botox, was $418m, up 16% from a year before and beating the $397.6m average estimate of seven analysts.
